Extending survival in patients with CLL: novel agents, MRD, and overcoming RT [Video]

Chaitra Ujjani, MD, University of Washington & Fred Hutchinson Cancer Research Center, Seattle, WA, outlines strategies to extend survival for patients with chronic lymphocytic leukemia (CLL). She mentions the utilization of novel agents instead of chemoimmunotherapies, using measurable residual disease (MRD) to guide treatment, and overcoming Richter’s transformation (RT). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.